美国血液学会2020年静脉血栓栓塞管理指南:深静脉血栓和肺栓塞的治疗
美国血液学会(ASH)基于系统评价与GRADE方法制定成人VTE治疗指南,涵盖初始管理、初级治疗、二级预防及复发VTE处理,共形成28条推荐。强推荐包括血流动力学受损的PE患者使用溶栓治疗、VTE二级预防使用维生素K拮抗剂时INR范围2.0至3.0、复发性无诱因VTE使用无限期抗凝;条件推荐包括低并发症风险的无并发症DVT和PE偏好家庭治疗而非住院治疗,以及VTE初级治疗偏好直接口服抗凝药而非VKA。
要点
- 血流动力学受损的PE患者强推荐溶栓治疗。
- VTE二级预防使用VKA时,强推荐INR范围2.0至3.0而非更低范围。
- 复发性无诱因VTE强推荐无限期抗凝。
核心结论
- ASH 2020指南对VTE治疗形成28条推荐,涵盖初始管理、初级治疗、二级预防和复发性VTE事件处理。
- 强推荐包括血流动力学受损的PE患者使用溶栓治疗、VTE二级预防使用VKA时INR范围2.0至3.0、复发性无诱因VTE使用无限期抗凝。
- 条件推荐包括低并发症风险的无并发症DVT和PE偏好家庭治疗而非住院治疗,以及VTE初级治疗偏好直接口服抗凝药而非VKA。
研究设计与样本
- ASH组建多学科指南专家组,平衡以减少利益冲突潜在偏倚。
- McMaster大学GRADE中心支持指南制定过程,包括更新或执行系统证据评价。
- 专家组根据对临床医生和成人患者的重要性优先排序临床问题和结局,采用GRADE方法评估证据并形成推荐,推荐草案经过公众评论。
主要发现
- 专家组就VTE初始管理、初级治疗、二级预防和复发性VTE事件治疗达成28条推荐。
关键数值与推荐
- 强推荐:血流动力学受损的PE患者使用溶栓治疗。
- 强推荐:VTE二级预防使用VKA时,INR范围2.0至3.0优于更低INR范围。
- 强推荐:复发性无诱因VTE患者使用无限期抗凝。
- 条件推荐:低并发症风险的无并发症DVT和PE偏好家庭治疗而非住院治疗。
- 条件推荐:VTE初级治疗偏好直接口服抗凝药而非VKA。
临床怎么用
- 对血流动力学受损的PE患者应使用溶栓治疗。
- VTE二级预防使用VKA时,应将INR控制在2.0至3.0。
- 复发性无诱因VTE患者应接受无限期抗凝。
- 低并发症风险的无并发症DVT和PE患者可优先选择家庭治疗。
- VTE初级治疗可优先选择直接口服抗凝药而非VKA。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), occurs in ∼1 to 2 individuals per 1000 each year, corresponding to ∼300 000 to 600 000 events in the United States annually. OBJECTIVE: These evidence-based guidelines from the American Society of Hematology (ASH) intend to support patients, clinicians, and others in decisions about treatment of VTE. METHODS: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and adult patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 28 recommendations for the initial management of VTE, primary treatment, secondary prevention, and treatment of recurrent VTE events. CONCLUSIONS: Strong recommendations include the use of thrombolytic therapy for patients with PE and hemodynamic compromise, use of an international normalized ratio (INR) range of 2.0 to 3.0 over a lower INR range for patients with VTE who use a vitamin K antagonist (VKA) for secondary prevention, and use of indefinite anticoagulation for patients with recurrent unprovoked VTE. Conditional recommendations include the preference for home treatment over hospital-based treatment for uncomplicated DVT and PE at low risk for complications and a preference for direct oral anticoagulants over VKA for primary treatment of VTE.
引用
- Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020. PMID: 33007077. doi:10.1182/bloodadvances.2020001830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。